Live Breaking News & Updates on Chris arington

Stay informed with the latest breaking news from Chris arington on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Chris arington and stay connected to the pulse of your community

Prasco Launches Authorized Generic of ZIOPTAN® Ophthalmic Solution

/PRNewswire/ -- Prasco Laboratories announced today the launch of the Authorized Generic of ZIOPTAN® (tafluprost ophthalmic solution) 0.0015%. This is Prasco's...

Ohio , United-states , Chris-arington , Pharma-inc , Merck-sharp-dohme-corp , Authorized-generic , Tafluprost-ophthalmic-solution , Ophthalmic-solution , Important-safety , Full-prescribing-information , Merck-sharp , Prasco-laboratories

Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Enters into an Exclusive Distribution Agreement with Prasco, LLC and Announces Commercial Launch of Loxapine Capsules

(1)
NORTHVALE, NJ / ACCESSWIRE / May 4, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today that its distribution and marketing partner Prasco, LLC ("Prasco"), has launched Elite's generic Loxapine capsules.
Elite entered a license, supply, and distribution agreement ("Agreement") with Prasco for Elite's Abbreviated New Drug Application (ANDA) for Loxapine Succinate capsules, 5 mg, 10 mg, 25 mg, and 50 mg ("Loxapine Capsules"). Loxapine is indicated for the treatment of schizophrenia and is currently listed on the FDA drug shortage list.
Prasco will be the exclusive U.S. distributor for Loxapine capsules, which will be marketed under Burel Pharmaceutical's label. Under the Agreement, Prasco will provide sales, marketing, and distribution for the product, and Elite will manufacture the product.

Ohio , United-states , Nasrat-hakim , Chris-arington , Exchange-commission , Lannett-company , Pharmaceuticals-inc , Glenmark-pharmaceuticals-inc , Elite-pharmaceuticals , Abbreviated-new-drug-application , Loxapine-succinate , Burel-pharmaceutical

Elite Pharmaceuticals Enters into an Exclusive Distribution Agreement with Prasco, LLC and Announces Commercial Launch of Loxapine Capsules

Elite Pharmaceuticals Enters into an Exclusive Distribution Agreement with Prasco, LLC and Announces Commercial Launch of Loxapine Capsules
ACCESSWIRE
05 May 2021, 00:31 GMT+10
NORTHVALE, NJ / ACCESSWIRE / May 4, 2021 / Elite Pharmaceuticals, Inc. ('Elite' or the 'Company') (OTCBB:ELTP) announced today that its distribution and marketing partner Prasco, LLC ('Prasco'), has launched Elite's generic Loxapine capsules.
Elite entered a license, supply, and distribution agreement ('Agreement') with Prasco for Elite's Abbreviated New Drug Application (ANDA) for Loxapine Succinate capsules, 5 mg, 10 mg, 25 mg, and 50 mg ('Loxapine Capsules'). Loxapine is indicated for the treatment of schizophrenia and is currently listed on the FDA drug shortage list.
Prasco will be the exclusive U.S. distributor for Loxapine capsules, which will be marketed under Burel Pharmaceutical's label. Under the Agreement, Prasco will provide sales, marketing, and distribution for the product, and Elite will manufacture the product.

Ohio , United-states , Nasrat-hakim , Chris-arington , Exchange-commission , Lannett-company , Pharmaceuticals-inc , Glenmark-pharmaceuticals-inc , Elite-pharmaceuticals , Abbreviated-new-drug-application , Loxapine-succinate , Loxapine-capsules